GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Conditions: Pancreatic Cancer
Interventions: Drug: Cyclophosphamide; Drug: Nivolumab; Drug: GVAX Pancreas Vaccine; Radiation: Stereotactic Body Radiation (SBRT)
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Bristol-Myers Squibb
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 1, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments